NiKang Therapeutics

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

• SCSean CaoDirector
• HCHong (Kelsey) ChenExecutive Officer
• WFWei FuDirector
• ZGZhenhai GaoDirector · Executive Officer
• TJTing JiaDirector
• RWRoderick WongDirector
• ZYZhengbin YaoDirector
• GYGary YeungDirector

• 18 Jun 2026Bifunctional Compounds Containing 2,5-SUBSTITUTED Pyrimidine Derivatives For Degrading Cyclin-dependent Kinase 2 Via Ubiquitin Proteasome Pathwayapplication
• 22 Jan 2026BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAYapplication
• 04 Dec 2025Bifunctional Compounds Containing Substituted Pyrimidine Derivatives For Degrading Cyclin-dependent Kinase 2 Via Ubiquitin Proteasome Pathwayapplication
• 27 Nov 2025Processes Of Making 3-FLUORO-5-(((1S,2AR)-1,3,3,4,4 PENTAFLUORO-2A-HYDROXY-2,2A,3,4-TETRAHYDRO-1H-CYCLOPENTA[CD]INDEN-7-YL)OXY)BENZONITRILE And Polymorphs Thereofapplication
• 06 Nov 2025TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE Derivatives As Hypoxia Inducible FACTOR-2(ALPHA) Inhibitorsapplication
• 07 Oct 2025Process Of Preparing 3-FLUORO-5(((1R,2AR)-3,3,4,4-TETRAFLUORO-1,2A-DIHYDROXY-2,2A,3,4-TETRAHYDRO-1H-CYCLOPENTA[CD]INDEN-7-YL)-OXY)BENZONITRILEgranted
• 16 Sept 2025PROCESSES OF MAKING 3-FLUORO-5-(((1S,2aR)-1,3,3,4,4-PENTAFLUORO-2a-HYDROXY-2,2a,3,4-TETRAHYDRO-1H-CYCLOPENTA[CD]INDEN-7-YL)OXY)-BENZONITRILE AND POLYMORPHS THEREOFgranted
• 19 Aug 2025TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE Derivatives As Hypoxia Inducible FACTOR-2(ALPHA) Inhibitorsgranted
• 17 Jun 2025Sulfonamido Derivatives As Cyclin-dependent Kinase 2 Inhibitorsgranted
• 01 Apr 2025Fused Tricyclic Ring Derivatives As Src HOMOLOGY-2 Phosphate Inhibitorsgranted
• 16 Jan 2025Compounds For Degrading Cyclin-dependent Kinase 2 Via Ubiquitin Proteosome Pathwayapplication
• 24 Dec 20242,3-DIHYDROBENZO[b]THIOPHENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORSgranted

• 07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
• 30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
• 30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
• 29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
• 26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
• 26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.